Key Highlights

  • Humacyte (NASDAQ:HUMA) finished Tuesday, November 10, 2026 at USD 0.5830, a 28.08% advance on a calculated prior close of USD 0.4552, or USD 0.1278 a share, placing it near the top of the day's US gainers for Canadian investors scanning cross-border names.
  • Trading reached 6.98 million shares, a relative Volume of 1.62, which points to a recent average near 4.31 million shares and roughly USD 4.07 million changing hands at the closing price (both calculated).
  • Per its November 2, 2026 notice, the company set its third-quarter and nine-month 2026 results, a Business update and an 8:00 a.m. ET webcast for November 10, 2026.
  • Market value stands at USD 161.96 million. Trailing diluted EPS is USD -0.49, EPS growth is -7.27%, no P/E applies and the Dividend Yield is 0.00%.

What Drove Humacyte on November 10 (+28.08%)

The regular session on Tuesday, November 10, 2026 closed with Humacyte at USD 0.5830, compared with a calculated USD 0.4552 the prior Monday, November 9, a 28.08% advance. The company had picked November 10 for its third-quarter 2026 report and webcast. On November 9 it also flagged a first-in-human coronary bypass study to be shown at the AHA Scientific Sessions 2026, following a November 3 notice about that meeting. Older items include an October 28 Patent for Symvess and other bioengineered tissues with protection through 2043, an October 23 Phase 3 finding in women at ASN Kidney Week favouring the ATEV over a fistula, and an October 15 update showing hospitals ordering Symvess up 44%, from 34 to 49, as of September 30. Figures inside the November 10 release could not be reviewed here.

The Rationale: A Results Day and Growing Commercial Traction

The catalyst identified is the scheduled third-quarter report alongside a string of clinical and commercial updates, although published coverage did not single out the item that attracted buyers. On September 9, 2026 the company said the FDA cleared a longer Symvess shelf life, 36 months instead of 18, which may cut product waste in hospitals. As general context, shares priced under USD 1.00 often swing hard around results, since slight shifts in Revenue or cash runway change dilution expectations. Adding 15 hospitals in a quarter signals uptake, but 49 hospitals do not equal profitability, and the trailing loss of USD 0.49 a share is about 84% of the share price (calculated).

Valuation, Liquidity and Risk Factors

A Market Value of USD 161.96 million implies roughly 277.8 million shares (calculated), so fresh Equity raised would dilute existing holders considerably. One published snapshot cited liquidity near USD 80 million and a monthly burn near USD 7 million, about eight months of runway, yet no filing confirmed it, so treat it as unverified. Trailing EPS growth of -7.27% indicates a wider loss. As general context, a price below USD 1.00 that persists can attract Nasdaq minimum bid attention. Relative volume of 1.62 shows above-average activity, but few trades can shift a price this low and spreads may widen. Nothing here suggests the advance will continue.

Where Things Stand

Humacyte (NASDAQ:HUMA) gained 28.08% to USD 0.5830 on November 10, 2026, a session that lined up with its scheduled third-quarter results and 8:00 a.m. ET webcast after a month of clinical and commercial headlines. The calculated prior close was USD 0.4552. With 6.98 million shares traded and a USD 161.96 million market value, it remains a high-risk name sensitive to dilution.